Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavoglurant in Adolescent Fragile X Syndrome
NCT01357239Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2011
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of mavoglurant in Fragile X syndrome (FXS), sponsored by Novartis. Started May 2011; status: completed.
02
Drugs
mavoglurant
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT01357239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01357239.